Commonwealth Equity Services LLC lowered its stake in shares of Cardlytics, Inc. (NASDAQ:CDLX) by 11.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,970 shares of the company’s stock after selling 503 shares during the quarter. Commonwealth Equity Services LLC’s holdings in Cardlytics were worth $333,000 at the end of the most recent quarter.
Other institutional investors also recently made changes to their positions in the company. US Bancorp DE grew its holdings in Cardlytics by 245.7% during the second quarter. US Bancorp DE now owns 242 shares of the company’s stock worth $31,000 after buying an additional 172 shares in the last quarter. Amundi bought a new stake in Cardlytics during the second quarter worth $194,000. Xponance Inc. bought a new stake in Cardlytics during the second quarter worth $222,000. Great West Life Assurance Co. Can grew its holdings in Cardlytics by 15.4% during the second quarter. Great West Life Assurance Co. Can now owns 1,902 shares of the company’s stock worth $241,000 after buying an additional 254 shares in the last quarter. Finally, PNC Financial Services Group Inc. bought a new stake in Cardlytics during the second quarter worth $330,000. Institutional investors and hedge funds own 93.50% of the company’s stock.
CDLX has been the subject of several recent research reports. Zacks Investment Research upgraded Cardlytics from a “sell” rating to a “hold” rating in a report on Tuesday, January 4th. Craig Hallum cut their price objective on Cardlytics from $120.00 to $100.00 and set a “buy” rating on the stock in a research report on Wednesday, November 3rd. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat, Cardlytics presently has a consensus rating of “Buy” and a consensus target price of $126.14.
Cardlytics (NASDAQ:CDLX) last issued its quarterly earnings results on Tuesday, November 2nd. The company reported ($0.84) EPS for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.02. Cardlytics had a negative return on equity of 13.92% and a negative net margin of 50.59%. The firm had revenue of $64.98 million for the quarter, compared to analysts’ expectations of $62.40 million. As a group, analysts forecast that Cardlytics, Inc. will post -2.99 earnings per share for the current fiscal year.
In other news, insider Kirk Somers sold 1,000 shares of the company’s stock in a transaction on Thursday, January 13th. The stock was sold at an average price of $67.97, for a total transaction of $67,970.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Scott D. Grimes sold 2,000 shares of the company’s stock in a transaction on Monday, October 18th. The shares were sold at an average price of $83.65, for a total value of $167,300.00. The disclosure for this sale can be found here. In the last ninety days, insiders have bought 168,690 shares of company stock worth $11,122,880 and have sold 108,037 shares worth $8,461,493. 6.50% of the stock is owned by corporate insiders.
Cardlytics Company Profile
Cardlytics, Inc engages in the development of marketing solutions through its purchase intelligence platform. It operates through the Cardlytics Direct and Other Platform Solutions segments. The Cardlytics Direct segment represents its proprietary native bank advertising channel. The Other Platform Solutions segment includes solutions that enable marketers and marketing service providers to leverage the power of purchase intelligence outside the banking channel.
Want to see what other hedge funds are holding CDLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cardlytics, Inc. (NASDAQ:CDLX).
Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.